Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

gar control," said John Amatruda, M.D., vice president, clinical research, Merck & Co., Inc. "This study examines the clinical effect of initial combination therapy with JANUVIA and metformin, the two drugs comprising JANUMET, over one year."

An important predictive factor of the magnitude of A1C reduction in response to anti-hyperglycemic therapy is a patient's starting level of A1C. In a subgroup analysis of patients grouped by severity of starting baseline A1C, treatment with JANUVIA 50 mg/metformin 1000 mg twice daily demonstrated increasing mean A1C reductions from baseline the higher the baseline A1C. A mean reduction of 3.1 percent was seen in patients with baseline A1C of 10 percent or more (n=17), while reductions of 2.2 percent, 1.7 percent, and 1.0 percent were seen with baseline A1C values of nine to 10 percent, eight to nine percent, and less than eight percent, respectively.

Investigational study showed JANUVIA significantly improved blood sugar control when added to sulfonylurea or to sulfonylurea and metformin vs. sulfonylurea or sulfonylurea and metformin alone (Poster #535-P; Study #035)

In this study, which was designed to examine the efficacy and safety of JANUVIA in patients with type 2 diabetes whose blood glucose levels were inadequately controlled (A1C levels of 7.5 percent to 10.5 percent) on a sulfonylurea (glimepiride) alone or on a sulfonylurea (glimepiride) plus metformin, JANUVIA demonstrated a significant mean difference from placebo in A1C of 0.9 percent in patients on glimepiride and metformin and 0.6 percent in patients on glimepiride alone (p less than 0.001 for both comparisons to the addition of placebo).

After a titration/stabilization period on glimepiride (at least 4 mg/day) with or without metformin (at least 1500 mg/day) and a 2-week placebo run-in, 441 patients with a mean baseline A1C of 8.3 percent were randomized to the addition of JANUVIA 100 mg once-daily or placebo for 24 weeks. Of thes
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:10/31/2014)... ANGELES , Oct. 30, 2014 Migranade, ... Relief will be available to the 36 million U.S. ... a platform technology that targets the actual cause of ... medications attack pain and not the source Migranade is ... medication category. MIGRANADE Migraine Relief is available at ...
(Date:10/31/2014)... -- AbbVie (NYSE: ABBV ) today announced ... 30, 2014. "Our third-quarter results ... double-digit growth from HUMIRA and several other key ... in the quarter excluding lipids," said Richard A. ... exceeded our outlook for the quarter and have ...
(Date:10/30/2014)... 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... the Tel Aviv area of ... WuXi,s broad platform of integrated R&D services to local ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2
(Date:10/31/2014)... 31, 2014 With all the preparations ... optometrist feels they may overlook one critical area – ... like concentration, school performance and even behavior. Typical children’s ... to identify progressive vision problems, and to address this ... a new initiative: The Awesome Eyes Student Vision Program. ...
(Date:10/31/2014)... 31, 2014 Energy Textiles has recently ... new gear is now available online, and Energy Textile ... of Celliant infrared-active athletic gear over compression gear. , ... contract has been signed for Under Armour to provide ... next eight years. In light of this decision, Energy ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Sleep apnea may make ... where you parked your car or left your house keys, ... severe sleep apnea showed that this ability -- called spatial ... movement (REM) sleep, even when other stages of sleep weren,t ... which dreams typically occur. "We,ve shown for the first ...
(Date:10/31/2014)... cost, patients with early stage breast cancer may ... proton therapy versus whole breast irradiation (WBI), according ... MD Anderson Proton Therapy Center. , ... patient characteristics, researchers used Medicare reimbursement codes to ... partial and whole breast irradiation therapies and treatment ...
(Date:10/31/2014)... one out of four older Americans say that either ... unwanted medical treatment, according to the latest issue of ... Aging Report ( PP&AR ), which goes on ... when they fail to honor patients, end-of-life health care ... Illness Care: Issues and Options ," features 12 articles ...
Breaking Medicine News(10 mins):Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Advance directives can benefit patients, families, and health care system 2
... N.Y., Jan. 10 With an eye to ... Mattress,Inc. ( http://www.bragada.com ) is now packing its ... high-end features than before., All Bragada Luxury ... vera built into the fabric. One of the ...
... ALF Regarding Her Battle ... with Hepatitis C, NEW ... dedicated to advocating on behalf of,Americans with liver disease, is proud announce ... of liver disease,including hepatitis C. To help spread the word about ALF,s ...
... to Compound Commonly Prescribed Hormone,Treatments, Use the Term ... In a series of,warning letters to compounding pharmacies ... has asserted a policy that would deny hundreds ... hormones,commonly, substituting its judgment for that of doctors. ...
... first Southern-style canned product ... American Heart Association, COLUMBUS, Ohio, Jan. 9 ... low fat and meatless, were the first,product line of ... savory,taste. Now, heart-healthy Sensibly Seasoned products also bear the ...
... Drew,s Question for Parents to be Featured on Yahoo! Answers -, ... Substance ... Abuse Treatment, NEW YORK, Jan. 9 ... of VH1,s new reality,series "Celebrity Rehab With Dr. Drew," is helping support ...
... affects 1% of all cases of developmental disorder, researchers say ... 16 appear to raise children,s risk for developing autism, a ... of autism researchers, pinpoints one of the causes of a ... its origins as it is in its symptoms. Not only ...
Cached Medicine News:Health News:Bragada(R) Luxury Mattress, Inc. Upgrades Luxury and Ultra Luxury Collections 2Health News:EHE International Supports the American Liver Foundation's Efforts at Raising Awareness for Hepatitis 2Health News:FDA Asserts New Policy to Restrict Women's Access to Bioidentical Hormones 2Health News:Glory Foods Receives Heart Healthy Certification 2Health News:Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM) 2Health News:Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM) 3Health News:Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM) 4Health News:Chromosome Abnormalities Raise Risk for Autism 2Health News:Chromosome Abnormalities Raise Risk for Autism 3Health News:Chromosome Abnormalities Raise Risk for Autism 4
Portex® pediatric tracheostomy tubes offer a choice in both form and fit. , ,The anatomical shape of the tube shaft along with the caudal angle of the 15 mm connector provide comfort and security...
... KIMBERLY-CLARK BALLARD Neonatal and ... Catheter features a multi ... deliver surfactants, lavage/irrigation port ... Multiple French sizes and ...
... spiral reinforced. X-ray opaque. Super safety low ... use. Adjustable Flange: The flange can be ... the thickness of the cervical soft tissue. ... the flange is tightly connected to the ...
... Portex® Blue Line ULTRA® Suctionaid® tracheostomy ... effective removal of secretions from above the ... Line ULTRA® Suctionaid® tracheostomy tubes provide an ... secretions from above the tracheostomy tube cuff ...
Medicine Products: